The European Medicines Agency has begun reviewing a new batch of products for potential pan-EU marketing approval, including vimseltinib and a recombinant pertussis vaccine (RPV), both of which could become first-of-their-kind treatments in the region.
Vimseltinib, from Deciphera Pharmaceuticals, is an investigational oral drug for treating tenosynovial giant cell tumor (TGCT). The standard treatment...








